Evaluation of the Impact of Antibody Fragments on Aggregation of Intact Molecules Via Size Exclusion Chromatography Coupled with Native Mass Spectrometry

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2024 Mar 27

PMID 38536719

Authors

Jing Xu

John E Coughlin

Malgorzata Szyjka

Serene Jabary

Sonal Saluja

Zoran Sosic

Yunqiu Chen

Chong-Feng Xu

Affiliations

Soon will be listed here.

Abstract

Aggregates are recognized as one of the most critical product-related impurities in monoclonal antibody (mAb)-based therapeutics due to their negative impact on the stability and safety of the drugs. So far, investigational efforts have primarily focused on understanding the causes and effects of mAb self-aggregation, including both internal and external factors. In this study, we focused on understanding mAb stability in the presence of its monovalent fragment, formed through hinge cleavage and loss of one Fab unit (referred to as "Fab/c"), a commonly observed impurity during manufacturing and stability. The Fab/c fragments were generated using a limited IgdE digestion that specifically cleaves above the IgG1 mAb hinge region, followed by hydrophobic interaction chromatographic (HIC) enrichment. Two IgG1 mAbs containing different levels of Fab/c fragments were incubated under thermally accelerated conditions. A method based on size exclusion chromatography coupled with native mass spectrometry (SEC-UV-native MS) was developed and used to characterize the stability samples and identified the formation of heterogeneous dimers, including intact dimer, mAb-Fab/c dimer, Fab/c-Fab/c dimer, and mAb-Fab dimer. Quantitative analyses on the aggregation kinetics suggested that the impact of Fab/c fragment on the aggregation rate of individual dimer differs between a glycosylated mAb (mAb1) and a non-glycosylated mAb (mAb2). An additional study of deglycosylated mAb1 under 25°C accelerated stability conditions suggests no significant impact of the N-glycan on mAb1 total aggregation rate. This study also highlighted the power of SEC-UV-native MS method in the characterization of mAb samples with regard to separating, identifying, and quantifying mAb aggregates and fragments.

Citing Articles

Progress in mass spectrometry approaches to profiling protein-protein interactions in the studies of the innate immune system.

Kim D, Nita-Lazar A J Proteins Proteom. 2024; 15(3):545-559.

PMID: 39380887 PMC: 11460538. DOI: 10.1007/s42485-024-00156-6.

References

Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D . Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol. 2011; 84:41-61. DOI: 10.1016/B978-0-12-386483-3.00004-5. View

Vlasak J, Ionescu R . Fragmentation of monoclonal antibodies. MAbs. 2011; 3(3):253-63. PMC: 3149706. DOI: 10.4161/mabs.3.3.15608. View

Wada R, Matsui M, Kawasaki N . Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs. 2018; 11(2):350-372. PMC: 6380427. DOI: 10.1080/19420862.2018.1551044. View

den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S . Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res. 2010; 28(4):920-33. PMC: 3063870. DOI: 10.1007/s11095-010-0297-1. View

Tamara S, den Boer M, Heck A . High-Resolution Native Mass Spectrometry. Chem Rev. 2021; 122(8):7269-7326. PMC: 9052423. DOI: 10.1021/acs.chemrev.1c00212. View

Gil D, Schrum A . Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Adv Biosci Biotechnol. 2015; 4(4a):73-84. PMC: 4307952. DOI: 10.4236/abb.2013.44A011. View

McKay A, Ruotolo B, Ilag L, Robinson C . Mass measurements of increased accuracy resolve heterogeneous populations of intact ribosomes. J Am Chem Soc. 2006; 128(35):11433-42. DOI: 10.1021/ja061468q. View

Nelson A, Dhimolea E, Reichert J . Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010; 9(10):767-74. DOI: 10.1038/nrd3229. View

Wu H, Kroe-Barrett R, Singh S, Robinson A, Roberts C . Competing aggregation pathways for monoclonal antibodies. FEBS Lett. 2014; 588(6):936-41. DOI: 10.1016/j.febslet.2014.01.051. View

10.

Desligniere E, Ehkirch A, Botzanowski T, Beck A, Hernandez-Alba O, Cianferani S . Toward Automation of Collision-Induced Unfolding Experiments through Online Size Exclusion Chromatography Coupled to Native Mass Spectrometry. Anal Chem. 2020; 92(19):12900-12908. DOI: 10.1021/acs.analchem.0c01426. View

11.

Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout B . Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J. 2010; 6(1):38-44. DOI: 10.1002/biot.201000091. View

12.

Zhou Q, Qiu H . The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins. J Pharm Sci. 2018; 108(4):1366-1377. DOI: 10.1016/j.xphs.2018.11.029. View

13.

Wang W, Singh S, Zeng D, King K, Nema S . Antibody structure, instability, and formulation. J Pharm Sci. 2006; 96(1):1-26. DOI: 10.1002/jps.20727. View

14.

Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

15.

Shah D, Zhang J, Maity H, Mallela K . Effect of photo-degradation on the structure, stability, aggregation, and function of an IgG1 monoclonal antibody. Int J Pharm. 2018; 547(1-2):438-449. DOI: 10.1016/j.ijpharm.2018.06.007. View

16.

Zhang H, Dalby P . Stability enhancement in a mAb and Fab coformulation. Sci Rep. 2020; 10(1):21129. PMC: 7713237. DOI: 10.1038/s41598-020-77989-w. View

17.

Gupta S, Jiskoot W, Schoneich C, Rathore A . Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy. J Pharm Sci. 2021; 111(4):903-918. DOI: 10.1016/j.xphs.2021.11.024. View

18.

Ren C, Bailey A, VanderPorten E, Oh A, Phung W, Mulvihill M . Quantitative Determination of Protein-Ligand Affinity by Size Exclusion Chromatography Directly Coupled to High-Resolution Native Mass Spectrometry. Anal Chem. 2018; 91(1):903-911. DOI: 10.1021/acs.analchem.8b03829. View

19.

Desligniere E, Ehkirch A, Duivelshof B, Toftevall H, Sjogren J, Guillarme D . State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis. Pharmaceuticals (Basel). 2021; 14(6). PMC: 8225019. DOI: 10.3390/ph14060498. View

20.

Chennamsetty N, Voynov V, Kayser V, Helk B, Trout B . Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B. 2010; 114(19):6614-24. DOI: 10.1021/jp911706q. View